UNSPSC 51332860: Metofenazate difumarate

This classification denotes a phenothiazine with the molecular formula C31H36ClN3O5S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2A3RCX7T4J, chemically known as benzoic acid, 3,4,5-trimethoxy-, 2-(4-(3-(2-chloro-10h-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester, (2e)-2-butenedioate (1:2), but more generally known as metofenazate difumarate, which bears US NIH Compound Identifier 6433198.

European Medicines Agency schedules metofenazate difumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08903MIG. Most nations, for tariff purposes, schedule metofenazate difumarate under HS 29343090. SMILES: COC1C(C(CC(C1)C(=O)OCCN2CCN(CC2)CCCN3C4C(CCC(C4)CL)SC5C3CCCC5)OC)OC.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51332860 Metofenazate difumarate is a Commodity code that designates a specific active pharmaceutical ingredient, yet recent state and local procurement activity under this code does not align with the ingredient's nominal scope. The three most recent solicitations tagged to this code—Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS Commission's RFI on direct-to-manufacturer prescriptions, and Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products—address pharmaceutical sourcing and community health supply chains rather than metofenazate difumarate specifically. State and local buyers using this code appear to include county health departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple jurisdictions. The actual purchasing activity reflects demand for naloxone kits, generic medications, OTC products, and specialized health systems rather than the narrow chemical compound the code nominally describes.

Recent opportunities span Florida, Texas, and Minnesota through cooperative and direct procurement channels. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the contract carries a two-year initial term with optional one-year renewal and includes FEMA compliance requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as an exploratory market-intelligence solicitation regarding direct-to-manufacturer pharmacy programs for state self-insured plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and operational compliance factors. The code shows little relevant recent activity aligned with its stated chemical scope.